<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809094</url>
  </required_header>
  <id_info>
    <org_study_id>SU-12112008-1378</org_study_id>
    <nct_id>NCT00809094</nct_id>
  </id_info>
  <brief_title>NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients</brief_title>
  <official_title>A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      This Phase IIB proof-of-concept study would examine the effects of an investigational product
      called N-acetylcysteine (NAC) on the basic processes that cause inflammation in CF lung
      disease. We hope to learn more about the causes of lung disease in cystic fibrosis by
      studying the characteristics of the inflammation in the lungs of patients who have CF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum</measure>
    <time_frame>From enrollment to end of the 24-week trial</time_frame>
    <description>(change in log10 HNE in the active treatment group) - (change in log10 HNE in the placebo group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 (Percent of Predicted for Age)</measure>
    <time_frame>From enrollment to the end of the 24-week trial</time_frame>
    <description>Change in forced expiratory volume in 1 second as compared to normals for age (percent of predicted)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (L)</measure>
    <time_frame>Baseline to end of study (24 weeks)</time_frame>
    <description>Forced expiratory volume in 1 second (Liters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEF 25-75% (L/Sec)</measure>
    <time_frame>Baseline to end of study (24 weeks)</time_frame>
    <description>Difference in mid-expiratory flow rates between 25 to 75% of the vital capacity, in L/sec measured at the beginning of the study to the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEF 25-75% (Percent of Predicted)</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to the end of study (24 weeks).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in DLCO (ml/Min/mmHg) Over Time by Treatment Group</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Change in the diffusing capacity of carbon monoxide across the lung measured from baseline to end of 24-week study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in ECHO Tricuspid Regurgitation (mm Hg) Over Time by Treatment Group</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Change in measure of estimated right ventricular pressure over the 24-week study period</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was administered oral tablet TID for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine (NAC)</intervention_name>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
    <other_name>PharmaNAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 7 years of age or older

          2. Diagnosis of CF based upon the following criteria:

               1. One or more clinical features characteristic of CF AND (b or c)

               2. Positive sweat test &gt; 60 mEq/L by quantitative pilocarpine iontophoresis

               3. A genotype with two identifiable mutations consistent with CF

          3. Written informed consent (and assent when applicable) obtained from subject or
             subject's legal representative

          4. Clinically stable with no evidence of acute upper or lower respiratory tract infection
             within 4 weeks prior to enrollment

          5. Stable mild or moderately severe lung disease defined by an FEV1 &gt; or = 40% and &lt; or =
             85% predicted for age based on the Wang (males &lt; 18 years, females &lt; 16 years) or
             Hankinson (males &gt; or = 18 years, females &gt; or = 16 years) standardized equations

          6. Able to tolerate sputum induction with 3% hypertonic saline and to expectorate

          7. Able to perform repeatable, consistent efforts in pulmonary function testing

          8. Weight &gt; or = 25 kg at time of enrollment

          9. Females of child bearing potential must be willing to use birth control (IUD, oral,
             transdermal, or parenteral contraceptives; abstinence)

        Exclusion Criteria:

          1. Clinically significant liver enzymes (AST, ALT or GGT) &gt; 2.5 times the upper limit of
             normal at screening

          2. History of ABPA, unless have evidence of a stable IgE (&lt; 5% increase compared to
             previous test) for 6 months prior to enrollment

          3. Current or history of rheumatic or collagen vascular disorders

          4. Use of NSAIDS other than for chronic therapy within 1 week prior to enrollment

          5. Initiation of chronic therapy with ibuprofen, azithromycin, TOBI® or Aztreonam within
             6 weeks prior to enrollment

          6. Consumption or inhalation of antioxidants (including NAC, GSH, Immunocal, Nacystelyn,
             pentoxyfilline) within 6 weeks prior to enrollment

          7. Use of oral or IV corticosteroids within 4 weeks prior to enrollment

          8. Use of acetaminophen within 3 days prior to enrollment

          9. Unable to forego during the study:

               -  Vitamin E: more than 400 IU/day for subjects &lt; or = 12 years of age and 800
                  IU/day for subjects &gt; 12 years of age

               -  Vitamin C: more than 0.5 gm/day

               -  More than two alcoholic drinks per day

         10. Known hypersensitivity to oral PharmaNAC®

         11. Current cigarette consumption

         12. Pregnant or breastfeeding

         13. Subject unlikely to complete the study as determined by the Investigator

         14. Any condition that the Investigator believes would interfere with the intent of this
             study or would make participation not in the best interest of the subject

         15. Participation in trials for other anti-inflammatory or therapeutic investigational
             drugs within 6 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol K. Conrad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Children</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The PennState Milton S Hersey Medical Ctr</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, Primary Children</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began 11/4/2008. Recruitment process was staggered: Stanford cohort first to focus on safety data related to potential pulmonary hypertension. After half of the Stanford cohort reached the 8-week time point, the DSMC evaluated PH safety data. The other sites then began enrollment. Final subject enrolled on 2/2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Drug</title>
          <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Drug</title>
          <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum</title>
        <description>(change in log10 HNE in the active treatment group) – (change in log10 HNE in the placebo group)</description>
        <time_frame>From enrollment to end of the 24-week trial</time_frame>
        <population>The primary endpoint analyses described uses the subset of the ITT population with complete case data. 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum</title>
          <description>(change in log10 HNE in the active treatment group) – (change in log10 HNE in the placebo group)</description>
          <population>The primary endpoint analyses described uses the subset of the ITT population with complete case data. 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
          <units>log10 mcg/mL</units>
          <param>Log Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-1.12" upper_limit="1.38"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-1.20" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there will be no difference in the change in human neutrophil activity measured from baseline to end of the study (24 weeks)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 (Percent of Predicted for Age)</title>
        <description>Change in forced expiratory volume in 1 second as compared to normals for age (percent of predicted)</description>
        <time_frame>From enrollment to the end of the 24-week trial</time_frame>
        <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 (Percent of Predicted for Age)</title>
          <description>Change in forced expiratory volume in 1 second as compared to normals for age (percent of predicted)</description>
          <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
          <units>percent of predicted vlaues</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.055" lower_limit="-26.16" upper_limit="25.73"/>
                    <measurement group_id="O2" value="-5.62" lower_limit="-24.54" upper_limit="19.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (L)</title>
        <description>Forced expiratory volume in 1 second (Liters)</description>
        <time_frame>Baseline to end of study (24 weeks)</time_frame>
        <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (L)</title>
          <description>Forced expiratory volume in 1 second (Liters)</description>
          <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
          <units>Liter</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="-21.92" upper_limit="30.28"/>
                    <measurement group_id="O2" value="-4.35" lower_limit="-25.00" upper_limit="22.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEF 25-75% (L/Sec)</title>
        <description>Difference in mid-expiratory flow rates between 25 to 75% of the vital capacity, in L/sec measured at the beginning of the study to the end of the study.</description>
        <time_frame>Baseline to end of study (24 weeks)</time_frame>
        <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>FEF 25-75% (L/Sec)</title>
          <description>Difference in mid-expiratory flow rates between 25 to 75% of the vital capacity, in L/sec measured at the beginning of the study to the end of the study.</description>
          <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
          <units>L/sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-0.39" upper_limit="0.88"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-1.22" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEF 25-75% (Percent of Predicted)</title>
        <description>Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to the end of study (24 weeks).</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>FEF 25-75% (Percent of Predicted)</title>
          <description>Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to the end of study (24 weeks).</description>
          <population>Out of 70 subjects randomized, 65 completed the Week 12 visit and 62 completed the study. There were 6 withdrawals in the NAC group and 2 in Placebo. Five out of 6 subjects in the NAC group withdrew due to subject decision. Missing data was not imputed.</population>
          <units>percent of predicted</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="-16.46" upper_limit="25.32"/>
                    <measurement group_id="O2" value="-3.81" lower_limit="-25.20" upper_limit="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in DLCO (ml/Min/mmHg) Over Time by Treatment Group</title>
        <description>Change in the diffusing capacity of carbon monoxide across the lung measured from baseline to end of 24-week study.</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <population>Sixteen subjects at Stanford University were enrolled as an initial safety cohort, and their data was used to evaluate the potential for NAC to cause PH in CF subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DLCO (ml/Min/mmHg) Over Time by Treatment Group</title>
          <description>Change in the diffusing capacity of carbon monoxide across the lung measured from baseline to end of 24-week study.</description>
          <population>Sixteen subjects at Stanford University were enrolled as an initial safety cohort, and their data was used to evaluate the potential for NAC to cause PH in CF subjects.</population>
          <units>ml/min/mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="2.86" lower_limit="-4.76"/>
                    <measurement group_id="O2" value="-1.39" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in ECHO Tricuspid Regurgitation (mm Hg) Over Time by Treatment Group</title>
        <description>Change in measure of estimated right ventricular pressure over the 24-week study period</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <population>Sixteen subjects at Stanford University were enrolled as an initial safety cohort, and their data was used to evaluate the potential for NAC to cause PH in CF subjects. 1 subject in NAC cohort has missing data. It was not imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECHO Tricuspid Regurgitation (mm Hg) Over Time by Treatment Group</title>
          <description>Change in measure of estimated right ventricular pressure over the 24-week study period</description>
          <population>Sixteen subjects at Stanford University were enrolled as an initial safety cohort, and their data was used to evaluate the potential for NAC to cause PH in CF subjects. 1 subject in NAC cohort has missing data. It was not imputed</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="6.02"/>
                    <measurement group_id="O2" value="31.75" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Drug</title>
          <description>N-acetylcysteine (NAC) :PharmaNAC® 900 mg effervescent tablets in blister packs were supplied by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identically packaged effervescent tablets that contained only the carrier were provided in blister packs by BioAdvantex Pharma, Inc. (Mississauga, ON, Canada)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Exacerbation</sub_title>
                <description>These events were not considered related to study drug by the treating physician</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="36"/>
                <counts group_id="E2" events="21" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced Expiratory Volume Decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>white blood cell count increased</sub_title>
                <description>s</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolitiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="55" subjects_affected="22" subjects_at_risk="36"/>
                <counts group_id="E2" events="45" subjects_affected="21" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carol Conrad</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-8325</phone>
      <email>cconrad@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

